Pentracor is a medical device company that has developed a breakthrough innovation for the treatment of acute myocardial infarction. Our first product on the German market is PentraSorb® CRP and has attracted much attention since the completion of a landmark clinical trial. Pentracor has a research and development pipeline in several therapeutic areas based on our unique expertise in immunology.
In heart attack and stroke, the C-reactive protein (CRP) leads to an increase of the primary damage. Further, the severity of rheumatic diseases is often determined by the amount of CRP.
The CRP adsorber (PentraSorb® CRP) is CE-marked. The corresponding Quality management system certificate according to EN ISO 13485 and the EC Certificate of Conformity in accordance with Directive 93/42/EEC are available.
Since November 2014 Pentracor GmbH is responsible and certified for the production and distribution of CRP adsorbers according to EN ISO 13485. The PentraSorb® CRP is an adsorber for the selective depletion of C-reactive protein (CRP).
Pentracor GmbH veröffentlich Jahresabschluss 2020 und erzielt gute Fortschritte im ersten Halbjahr 2021
Hennigsdorf, 28.07.2021 – Das Medizintechnik-Unternehmen Pentracor GmbH mit Sitz in Hennigsdorf bei
Berlin hat seinen Jahresabschluss 2020 veröffentlicht. Das Geschäftsjahr war geprägt vom Roll-out des vom
Unternehmen entwickelten und zertifizierten Medizinprodukts PentraSorb® CRP sowie der Initiierung und Durchführung von klinischen Studien, um die Akzeptanz für die CRP-Apherese in der Behandlung von Krankheiten, die mit einer akuten Entzündung wie Herzinfarkt einhergehen, zu erhöhen.
Article about the CAMI-1 study published in "Intensiv-News"
12.07.2021
In the 3rd issue of "Intensiv-News" 2021, the most recent publications on CRP apheresis were summarized and evaluated with a focus on the recently published CAMI-1 study.
Pentracor nominated for the "Zukunftspreis Brandenburg" 2021
Twelve companies have been nominated by the main jury for the "Zukunftspreis Brandenburg" 2021. Six prize winners and one company as a special prize winner will be awarded Brandenburg's most important business prize in the final on November 12 at the Airport Center Berlin Schönefeld. Pentracor GmbH, based in Hennigsdorf, is among the nominees. "We are very honored by the nomination," said Pentracor CEO Dr. Ahmed Sheriff.
Interview with Dr. Ahmed Sheriff on CRP apheresis for COVID-19 patients
08.06.2021
ntv has broadcast an interview with Dr. Ahmed Sheriff about CRP apheresis for COVID-19 patients. Among other things, they talk about the lack of funding for medical devices in the Corona Pandemic.
ZDF reports on CRP apheresis as salvation for COVID-19 patients
18.05.2021
ZDF has reported on CRP apheresis treatment for COVID-19 patients.
At the Klinikum Havelhöhe, the therapy is now used for many severely ill Corona patients - with promising results. Nevertheless, all funding applications for a large clinical trial were unsuccessfully rejected. The trial is needed to make the therapy available to COVID-19 patients throughout Germany.
